Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Cybin Inc (CYBN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: CYBN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $84.61
1 Year Target Price $84.61
| 4 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -59.58% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 143.66M USD | Price to earnings Ratio - | 1Y Target Price 84.61 |
Price to earnings Ratio - | 1Y Target Price 84.61 | ||
Volume (30-day avg) 5 | Beta 1.11 | 52 Weeks Range 4.81 - 13.88 | Updated Date 09/13/2025 |
52 Weeks Range 4.81 - 13.88 | Updated Date 09/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.44 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -34.25% | Return on Equity (TTM) -54.31% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 88632843 | Price to Sales(TTM) 278.25 |
Enterprise Value 88632843 | Price to Sales(TTM) 278.25 | ||
Enterprise Value to Revenue 313.59 | Enterprise Value to EBITDA -3.79 | Shares Outstanding 23590000 | Shares Floating 19718108 |
Shares Outstanding 23590000 | Shares Floating 19718108 | ||
Percent Insiders 98.65 | Percent Institutions 38.53 |
Upturn AI SWOT
Cybin Inc
Company Overview
History and Background
Cybin Inc. is a biopharmaceutical company focused on psychedelic drug development. Founded in 2019, Cybin aims to address mental health disorders by developing novel psychedelic molecules and delivery systems. They've grown through acquisitions and partnerships, focusing on research and clinical trials.
Core Business Areas
- Drug Discovery and Development: Focuses on discovering and developing novel psychedelic molecules, including deuterated tryptamines.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates for mental health conditions like depression and anxiety.
- Drug Delivery Systems: Developing innovative drug delivery systems to improve the bioavailability and efficacy of psychedelic compounds.
Leadership and Structure
Cybin's leadership team includes Doug Drysdale (CEO), Amir Inamdar (CFO), and Dr. Amir Kalali (Chief Medical Officer). The company operates with a focus on research, clinical development, and regulatory affairs.
Top Products and Market Share
Key Offerings
- CYB003 (Deuterated Psilocybin Analog): CYB003 is Cybin's lead drug candidate, a deuterated psilocybin analog being developed for Major Depressive Disorder. Market share data is not yet available as it is in clinical trials. Competitors in psilocybin research include COMPASS Pathways and MindMed.
- CYB004 (Modified Tryptamine): CYB004 is an orally dissolving film formulation of DMT. Market share data is not yet available as it is in clinical trials. Competitors in DMT research include Small Pharma and GH Research.
Market Dynamics
Industry Overview
The psychedelic drug development industry is experiencing rapid growth, driven by increasing awareness of the potential of psychedelics to treat mental health disorders. Regulatory landscapes are evolving, with some jurisdictions showing openness to psychedelic therapies.
Positioning
Cybin is positioned as an innovator in the psychedelic drug development space, particularly in deuterated compounds and novel delivery methods. Its competitive advantage lies in its intellectual property and clinical trial programs.
Total Addressable Market (TAM)
The TAM for mental health treatments is estimated to be in the billions of dollars. Cybin is positioned to capture a portion of this market by developing effective psychedelic therapies.
Upturn SWOT Analysis
Strengths
- Innovative drug development pipeline
- Strong intellectual property portfolio
- Experienced leadership team
- Focus on novel drug delivery systems
Weaknesses
- Early stage development
- Limited revenue generation
- High cash burn rate
- Regulatory uncertainty
Opportunities
- Positive clinical trial results
- Regulatory approvals
- Partnerships with pharmaceutical companies
- Expanding market demand for mental health treatments
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other psychedelic drug developers
- Negative public perception
Competitors and Market Share
Key Competitors
- COMPASS Pathways (CMPS)
- MindMed (MNMD)
- GH Research (GHRS)
Competitive Landscape
Cybin differentiates itself through its focus on deuterated compounds and novel drug delivery systems. It competes with other psychedelic drug developers based on the strength of their clinical trial data, intellectual property, and partnerships.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is measured by the expansion of the drug pipeline, completion of preclinical studies, and initiation of clinical trials.
Future Projections: Future growth is contingent on positive clinical trial results, regulatory approvals, and commercialization of its drug candidates.
Recent Initiatives: Recent initiatives include advancing CYB003 into Phase 2 clinical trials, developing new drug delivery systems, and strengthening its intellectual property portfolio.
Summary
Cybin Inc. is an early-stage biopharmaceutical company focused on psychedelic drug development. The company's strengths lie in its innovative drug pipeline and experienced leadership. However, its weaknesses include limited revenue and regulatory uncertainty. Positive clinical trial results and regulatory approvals are crucial for future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Cybin Inc. Investor Relations
- SEC Filings
- Company Press Releases
- Third-party industry reports
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cybin Inc
Exchange NYSE MKT | Headquaters Toronto, ON, Canada | ||
IPO Launch date 2019-09-13 | Co-Founder, Interim CEO, President & Executive Chairman Mr. Eric So L.L.B. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 50 | Website https://cybin.com |
Full time employees 50 | Website https://cybin.com | ||
Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds. It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.